nach oben

Erschienen in:

09.03.2019 | Preclinical study

Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer

verfasst von: Jilai Tian, Xiang Chen, Shengling Fu, Ruijie Zhang, Li Pan, Yang Cao, Xiaojuan Wu, Hui Xiao, Huey-Jen Lin, Hui-Wen Lo, Ying Zhang, Jiayuh Lin

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) has been ranked as one of the devastating malignancy worldwide. Its disease progression and treatment obstacle is associated with the negligible expression of estrogen receptors (ER⁻), progesterone receptors (PR⁻), and HER2 (HER2⁻). Due to a lack of growth hormone receptors, TNBC is desperately demanding effective therapeutic regimens. A growing body of evidence indicated that glycoprotein 130 kDa (GP130), the pivotal mediator involved in interleukin 6 (IL-6) and signal transducer and activator of transcription 3 (STAT3) signaling pathways, is strongly correlated with tumor progression. Therefore, GP130 could become a novel target for treating TNBC. In our earlier studies, we demonstrated bazedoxifene as being a novel GP130 inhibitor.

Methods

In the current report, anti-tumor effect of bazedoxifene on TNBC was further evaluated in TNBC cell lines SUM159, MDA-MB-231, and MDA-MB-468. We assessed anti-TNBC potency of bazedoxifene by carrying out various analysis encompassing western blot, cell proliferation, cell migration, colony formation, and growth of tumors in the xenograft mice.

Results

Our findings demonstrated that bazedoxifene not only decreased the expression of P-STAT3, IL-6/GP130-mediated downstream target genes P-AKT and P-ERK, but also blocked mitogen effects stimulated by IL-6, including cell viability, and overall cell survive, proliferation as well as cell migration. Likewise in laboratory animal model, tumor growth in mice was remarkably suppressed by bazedoxifene via an oral administration route. Combinational treatment of bazedoxifene plus the conventional chemotherapeutic agent, paclitaxel, synergistically impeded cell viability, colony formation, and cell migration far more significantly than the one from single-drug alone.

Conclusions

Taken together, our data suggest that bazedoxifene may be developed as a promising small molecular therapeutic agent for eradicating TNBC intrinsically associated with constitutively active IL-6/GP130/STAT3 signaling cascade.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289. https://doi.org/10.3322/caac.21349 CrossRefPubMed

Heo T, Wahler J, Suh N (2016) Potential therapeutic implications targeting agents in breast cancer. Oncotarget 7:15460–15473PubMedPubMedCentral

Bharti R, Dey G, Mandal M (2016) Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: a snapshot of IL-6 mediated involvement. Cancer Lett 375:51–61. https://doi.org/10.1016/j.canlet.2016.02.048 CrossRefPubMed

Boulanger MJ, Chow D, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300:2101–2104. https://doi.org/10.1126/science.1083901 CrossRefPubMed

Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102:4700–4705. https://doi.org/10.1073/pnas.0409894102 CrossRefPubMedPubMedCentral

Dethlefsen C, Højfeldt G, Hojman P (2013) The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 138:657–664. https://doi.org/10.1007/s10549-013-2488-z CrossRefPubMed

Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9:626–633. https://doi.org/10.2174/156652409788488720 CrossRefPubMed

Real PJ, Sierra A, De Juan A et al (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21:7611–7618. https://doi.org/10.1038/sj.onc.1206004 CrossRefPubMed

10.

Saini U, Naidu S, ElNaggar A et al (2017) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36:168–181. https://doi.org/10.1038/onc.2016.197 CrossRefPubMed

11.

Mui ALF (1999) The role of STATs in proliferation, differentiation, and apoptosis. Cell Mol Life Sci 55:1547–1558. https://doi.org/10.1007/s000180050394 CrossRefPubMed

12.

Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51. https://doi.org/10.1038/nri1995 CrossRefPubMed

13.

Jones SA, Scheller J, Rose-john S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121:3375–3383. https://doi.org/10.1172/JCI57158.but CrossRefPubMedPubMedCentral

14.

Li H, Xiao H, Lin L et al (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J Med Chem 57:632–641. https://doi.org/10.1021/jm401144z CrossRefPubMed

15.

Yadav A, Kumar B (2017) Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer. Oncotarget 8:66912–66924CrossRefPubMed

16.

Wu X, Cao Y, Xiao H et al (2016) Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy. Mol Cancer Ther 15:2609–2619. https://doi.org/10.1158/1535-7163.MCT-15-0921 CrossRefPubMedPubMedCentral

17.

Oshima T, Cao X, Grande F et al (2009) Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs 20:312–320. https://doi.org/10.1097/CAD.0b013e328323a7ca CrossRefPubMed

18.

Xu S, Grande F, Garofalo A, Neamati N (2013) Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther 12:937–949. https://doi.org/10.1158/1535-7163.MCT-12-1082 CrossRefPubMed

19.

Lin L, Hutzen B, Zuo M et al (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70:2445–2454. https://doi.org/10.1158/0008-5472.CAN-09-2468 CrossRefPubMedPubMedCentral

20.

Ataie-Kachoie P, Pourgholami MH, Richardson DR, Morris DL (2014) Gene of the month: interleukin 6 (IL-6). J Clin Pathol 67:932–937. https://doi.org/10.1136/jclinpath-2014-202493 CrossRefPubMed

21.

Chun J, Li RJ, Cheng MS, Kim YS (2015) Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett 357:393–403. https://doi.org/10.1016/j.canlet.2014.11.049 CrossRefPubMed

22.

Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548–2556. https://doi.org/10.1038/sj.onc.1203551 CrossRefPubMed

23.

Chang J, Koh AJ, Roca H, Mccauley LK (2015) Juxtacrine interaction of macrophages and bone marrow stromal cells induce interleukin-6 signals and promote cell migration. Bone Res 3:15014. https://doi.org/10.1038/boneres.2015.14 CrossRefPubMedPubMedCentral

24.

Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265. https://doi.org/10.1038/nr1317 CrossRefPubMed

25.

Mustacchi G, de Laurentiis M (2015) The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther 9:4303–4318. https://doi.org/10.2147/DDDT.S86105 CrossRefPubMedPubMedCentral

26.

Bianchini G, Balko JM, Mayer IA et al (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674–690. https://doi.org/10.1038/nrclinonc.2016.66 CrossRefPubMedPubMedCentral

27.

Pickar JH, Komm BS (2015) Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: a review of effects on the breast. Post Reprod Heal 21:112–121. https://doi.org/10.1177/2053369115599090 CrossRef

28.

Lewiecki EM (2007) Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 16:1663–1672. https://doi.org/10.1517/13543784.16 CrossRefPubMed

29.

Sharifi M, Lewiecki EM (2014) Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol 7:281–291. https://doi.org/10.1586/17512433.2014.893819 CrossRefPubMed

30.

Tella SH, Gallagher JC (2013) Bazedoxifene+ conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause. Expert Opin Pharmacother 14:2407–2420. https://doi.org/10.1517/14656566.2013.844790 CrossRefPubMed

31.

Kharode Y, Bodine PVN, Miller CP et al (2008) The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149:6084–6091. https://doi.org/10.1210/en.2008-0817 CrossRefPubMed

32.

Manna S, Holz MK (2016) Tamoxifen action in ER-negative breast cancer. Sign Transduct Insights 5:1–7. https://doi.org/10.4137/STI.S29901 CrossRefPubMedPubMedCentral

33.

Jones ME, van Leeuwen FE, Hoogendoorn WE et al (2012) Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 14:R91. https://doi.org/10.1186/bcr3206 CrossRefPubMedPubMedCentral

34.

Lavie O, Barnett-griness O, Narod SA, Rennert G (2008) The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer 18:352–356CrossRefPubMed

35.

Rieck G, Freites O, Williams S (2005) Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol (Lahore) 25:39–41. https://doi.org/10.1080/01443610400024740 CrossRef

36.

Archer DF, Pinkerton JV, Utian WH et al (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109–1115. https://doi.org/10.1097/gme.0b013e3181a818db CrossRefPubMed

37.

Palacios S, de Villiers TJ, Nardone FDC et al (2013) Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 76:81–87. https://doi.org/10.1016/j.maturitas.2013.06.008 CrossRefPubMed

38.

Komm BS, Kharode YP, Bodine PVN et al (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999–4008. https://doi.org/10.1210/en.2005-0030 CrossRefPubMed

39.

Chines AA, Komm BS (2009) Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs Today 45:507–520

40.

Wardell SE, Nelson ER, Chao CA, McDonnell DP (2013) Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 19:2420–2431. https://doi.org/10.1158/1078-0432.CCR-12-3771 CrossRefPubMedPubMedCentral

41.

Lewis-Wambi J, Kim H, Curpan R et al (2011) The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Mol Pharmacol 80:610–620. https://doi.org/10.1124/mol.111.072249 CrossRefPubMedPubMedCentral

42.

Nair A, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27. https://doi.org/10.4103/0976-0105.177703 CrossRefPubMedPubMedCentral

43.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379:432–444. https://doi.org/10.1016/j.breastdis.2013.01.026 CrossRef

44.

Wang Y, Qu Y, Niu XL et al (2011) Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56:365–375. https://doi.org/10.1016/j.cyto.2011.06.005 CrossRefPubMed

45.

Mochizuki D, Adams A, Warner KA et al (2015) Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget 6:22822–22835. https://doi.org/10.18632/oncotarget.4477 CrossRefPubMedPubMedCentral

46.

Peng L, Luo Q, Lu H (2017) Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine (Baltimore) 96:49

47.

Rossini M, Lello S, Sblendorio I et al (2013) Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Devel Ther 7:601–610CrossRefPubMedPubMedCentral

Titel: Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
verfasst von: Jilai Tian
Xiang Chen
Shengling Fu
Ruijie Zhang
Li Pan
Yang Cao
Xiaojuan Wu
Hui Xiao
Huey-Jen Lin
Hui-Wen Lo
Ying Zhang
Jiayuh Lin
Publikationsdatum: 09.03.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05183-2

Springer Medizin

Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer